Enoxaparin Sodium is one of the most widely used low molecular weight heparin APIs for thrombosis prevention, postoperative anticoagulation and dialysis treatment. Global pharmaceutical manufacturers raise stricter standards for molecular weight distribution, impurity control and batch repeatability of Enoxaparin Sodium. Poorly controlled depolymerization technology leads to unstable pharmacological activity, which will hinder drug registration in North America, Europe and other high-end markets.

　　Jiulong specializes in the R&D and production of heparin series APIs. Our Enoxaparin Sodium adopts precise depolymerization and multi-stage purification technology to achieve narrow molecular distribution, consistent anti-Xa and anti-IIa activity ratio. All production lines follow GMP management standards, and every batch undergoes comprehensive laboratory testing before delivery. We provide full documentation packages including certificates of analysis, process records and impurity testing reports to support clients’ global registration applications.

　　Many overseas pharmaceutical buyers face supply instability and incomplete document issues when sourcing Enoxaparin Sodium. Jiulong builds stable raw material supply chains and maintains reasonable inventory to shorten delivery cycles. We support flexible order volumes, from lab trial batches to mass commercial supply. Our quality assurance team cooperates closely with clients to respond to audit requirements from international drug authorities.

　　For long-term stable procurement of qualified anticoagulant raw materials, reach out to Jiulong to discuss Enoxaparin Sodium specifications, sample application and customized cooperation solutions.